| Category | BioTech |
| Phone | 954-233-8746 |
| Employees | |
| Founded | 1979 |
| TOTAL | $9.43M |
| VENTURE FUNDING TOTAL | $9.43M |
| Venture Round, 9/05 PEF Advisors | $1.23M |
| Venture Round, 3/06 | $5.2M |
| Venture Round, 4/07 RAB Capital | $3M |
Viragen, together with its subsidiaries, engages in the research, development, manufacture, and commercialization of therapeutic proteins for the treatment of cancers and viral diseases in humans. Its product and product candidate portfolio includes Multiferon, a human alpha interferon product that comprise multiple subtype alpha interferons for the treatment of various infectious diseases and cancers; VG101 a therapeutic humanized monoclonal antibody targeting the treatment of malignant melanoma; and VG102 a therapeutic humanized antibody designed for the treatment of various solid tumors. The company also develops Avian Transgenics technology for production of human therapeutic proteins and antibodies. It operates in the United States, Scotland, and Sweden. The company was founded in 1979 and is headquartered in Plantation, Florida.
